A(
Therapeutic Areas
OpGen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Acuitas AMR Gene Panel | Detection of antibiotic resistance genes from bacterial isolates | Commercial |
| Acuitas AMR Gene Panel (ucp) | Urinary tract infection (UTI) pathogen ID & resistance detection | FDA Submission |
| Unyvero A50 RQ | Lower respiratory tract infections (LRTI) | Commercial |
| Unyvero A50 ITI | Implant & tissue infections | Commercial |
| Unyvero A50 BCU | Bloodstream infections | Commercial |
| Unyvero A50 UTI | Urinary tract infections | Commercial |
Leadership Team at OpGen
OS
Oliver Schacht
President, Chief Executive Officer, and Director
TC
Timothy C. Dec
Chief Financial Officer
AJ
Alfredo J. Mendez
Chief Scientific Officer
J(
Johannes (Jan) G. (Gert) B. Casselman
Chief Medical Officer
DL
David Lazar
Chief Commercial Officer
EJ
Evan/Evran Jones
Chairman of the Board
A(
Albert (Al) G. Baehny
Director
KL
Karin L. Eastham
Director
R(
Robert (Bob) G. Hausmann
Director
VM
Vadim M. Sapiro
Director